By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Argos Therapeutics, Inc. (Formerly Merix Bioscience) 

4233 Technology Drive

Durham  North Carolina  27704  U.S.A.
Phone: 919-287-6300 Fax: 919-287-6301


SEARCH JOBS


Industry
Biotechnology


Collaborations

Duke University  Exclusive license to the RNA based vaccine technology.

Rockefeller University  Exclusive worldwide rights to technology developed at Rockefeller relating to generation of dendritic cells.

Baylor University  Clinical and preclinical research in Lupus.

Kirin Brewery Co., Ltd.  The companies will collaborate to develop and commercialize dendritic cell vaccines, initially in the areas of cancer and infectious diseases.

Erlangen University  Clinical and preclinical research in Melanoma.





Company News
Argos Therapeutics, Inc. (ARGS) Recognized For Economic Development At The 17th Annual Triangle CREW Champion Awards 4/23/2015 10:47:28 AM
Argos Therapeutics, Inc. (ARGS) Announces Publication Of Data From Phase 2 Clinical Trial Of AGS-003 Fully Personalized Immunotherapy For Treatment Of Metastatic Renal Cell Carcinoma (mRCC) 4/21/2015 8:00:06 AM
Argos Therapeutics, Inc. (ARGS) To Present Update On Pivotal Phase 3 ADAPT Clinical Trial During 2015 ASCO Annual Meeting 4/20/2015 7:47:27 AM
Argos Therapeutics, Inc. (ARGS) Licenses Arcelis Technology Platform To Lummy HK For Development Of Personalized Immunotherapies To Treat Cancer In China 4/15/2015 4:01:36 PM
Argos Therapeutics, Inc. (ARGS) To Present At The 14th Annual Needham Healthcare Conference 4/8/2015 8:09:18 AM
Argos Therapeutics, Inc. (ARGS) Reports Fourth Quarter And Year-End 2014 Financial Results 3/31/2015 6:53:49 AM
Argos Therapeutics, Inc. (ARGS) Director Of Immunology To Present At HIV Vaccines Meeting 3/20/2015 7:36:12 AM
Argos Therapeutics, Inc. (ARGS) To Hold Fourth Quarter And Year-End 2014 Financial Results Conference Call On Monday, March 30, 2015 3/17/2015 7:39:55 AM
Argos Therapeutics, Inc. (ARGS) To Present At Three Upcoming Investor Conferences In March 3/5/2015 7:52:50 AM
Argos Therapeutics, Inc. (ARGS) Announces Update On Phase 3 ADAPT Trial To Be Presented During 2015 ASCO Genitourinary Cancers Symposium 2/27/2015 7:14:23 AM
12345678910...
//-->